CytoSorbents CTSO releases its next round of earnings this Tuesday, August 04. Here's Benzinga's essential guide to CytoSorbents's Q2 earnings report.
Earnings and Revenue
CytoSorbents's EPS is expected to be at $-0.08 on sales of $9.66 million, according to Wall Street analysts.In the same quarter last year, CytoSorbents posted a loss of $-0.110 per share on sales of $6.23 million. If the company were to post earnings in-line with the consensus estimate when it reports Tuesday, EPS would be down 27.27%. Sales would be up 38.0% from the year-ago period. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.17 | -0.22 | -0.14 |
| EPS Actual | -0.10 | -0.12 | -0.21 | -0.11 |
| Revenue Estimate | 7.00 M | 6.80 M | 6.66 M | 6.17 M |
| Revenue Actual | 8.71 M | 7.43 M | 6.09 M | 6.23 M |
Stock Performance
Over the last 52-week period, shares are up 45.87%. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Don't be surprised to see the stock move on comments made during its conference call. CytoSorbents is scheduled to hold the call at 16:45:00 ET and can be accessed here: https://viavid.webcasts.com/starthere.jsp?ei=1338510&tp_key=e984a6c557
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
